Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014). Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition. The American Society for Pharmacology and Experimental Therapeutics.

Murai, Junko, Yiping Zhang, Joel Morris, Jiuping Ji, Shunichi Takeda, James H. Doroshow, e Yves Pommier. Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy With Camptothecins or Temozolomide Based On PARP Trapping Versus Catalytic Inhibition. The American Society for Pharmacology and Experimental Therapeutics, 2014.

Murai, Junko, et al. Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy With Camptothecins or Temozolomide Based On PARP Trapping Versus Catalytic Inhibition. The American Society for Pharmacology and Experimental Therapeutics, 2014.